Know Labs, Inc. Overview
Pro stress-test →Know Labs is a US-based medical device company developing proprietary radio frequency dielectric spectroscopy (RFDS) technology for non-invasive health monitoring, primarily focused on continuous glucose monitoring for diabetes management. The company represents a classic pre-commercial biotech venture targeting FDA approval and commercialization of its innovative sensor platform.
Strategic Profile
Pro stress-test →Know Labs operates at the intersection of medical diagnostics and wearable technology, with a differentiated technology approach using electromagnetic spectroscopy to capture unique molecular signatures without invasive procedures. The company has recently undergone significant strategic transformation, with founder Ron Erickson continuing diagnostic research while new leadership pursues broader digital asset and blockchain initiatives following an acquisition by Greg Kidd's Goldeneye 1995, LLC in mid-2025.
Competitive Landscape
Pro stress-test →Know Labs competes in the continuous glucose monitoring (CGM) market against established players like Dexcom, Abbott FreeStyle Libre, and Medtronic Guardian. The non-invasive technology positioning offers potential differentiation if successfully commercialized, though numerous competitors pursue similar non-invasive glucose monitoring approaches. The company's recent pivot toward blockchain and digital assets creates uncertainty regarding competitive focus and resource allocation to core diagnostics business.
Industry Context
Know Labs, Inc. operates in Medical Devices / Biotech - Diabetes Management & Non-invasive Diagnostics.
Key facts
Founded: 1998 · Headquarters: Reno, Nevada